Patrick Machado - Net Worth and Insider Trading
Patrick Machado Net Worth
The estimated net worth of Patrick Machado is at least $1.5 Billion dollars as of 2024-11-13. Patrick Machado is the 10% Owner of Myovant Sciences Ltd and owns about 40,765,599 shares of Myovant Sciences Ltd (MYOV) stock worth over $1.1 Billion. Patrick Machado is the 10% Owner of Urovant Sciences Ltd and owns about 22,860,013 shares of Urovant Sciences Ltd (UROV) stock worth over $371 Million. Patrick Machado is also the 10% Owner of Sio Gene Therapies Inc and owns about 13,244,048 shares of Sio Gene Therapies Inc (SIOX) stock worth over $6 Million. Besides these, Patrick Machado also holds Medivation Inc (MDVN) , Adverum Biotechnologies Inc (ADVM) , Chimerix Inc (CMRX) , SCYNEXIS Inc (SCYX) . Details can be seen in Patrick Machado's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Patrick Machado has not made any transactions after 2021-03-24 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Patrick Machado
Patrick Machado Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Patrick Machado owns 17 companies in total, including Principia Biopharma Inc (PRNB) , Adverum Biotechnologies Inc (ADVM) , and Turning Point Therapeutics Inc (TPTX) among others .
Click here to see the complete history of Patrick Machado’s form 4 insider trades.
Insider Ownership Summary of Patrick Machado
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
PRNB | Principia Biopharma Inc | 2020-09-28 | director |
ADVM | Adverum Biotechnologies Inc | 2021-03-24 | director |
TPTX | Turning Point Therapeutics Inc | 2019-05-13 | director |
2015-12-29 | director | ||
2019-12-10 | director | ||
2016-10-18 | 10 percent owner | ||
2019-03-18 | 10 percent owner | ||
2019-06-04 | 10 percent owner | ||
2019-07-10 | other: Former 10% Owner | ||
2016-09-15 | director | ||
2018-12-21 | director | ||
2016-08-17 | director | ||
2016-09-28 | director | ||
2023-06-02 | director | ||
2021-10-01 | director | ||
2023-05-04 | director | ||
2023-07-20 | director |
Patrick Machado Latest Holdings Summary
Patrick Machado currently owns a total of 7 stocks. Among these stocks, Patrick Machado owns 40,765,599 shares of Myovant Sciences Ltd (MYOV) as of June 4, 2019, with a value of $1.1 Billion and a weighting of 74.17%. Patrick Machado owns 22,860,013 shares of Urovant Sciences Ltd (UROV) as of June 19, 2019, with a value of $371 Million and a weighting of 25.04%. Patrick Machado also owns 13,244,048 shares of Sio Gene Therapies Inc (SIOX) as of March 18, 2019, with a value of $6 Million and a weighting of 0.43%. The other 4 stocks Medivation Inc (MDVN) , Adverum Biotechnologies Inc (ADVM) , Chimerix Inc (CMRX) , SCYNEXIS Inc (SCYX) have a combined weighting of 0.37% among all his current holdings.
Latest Holdings of Patrick Machado
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
MYOV | Myovant Sciences Ltd | 2019-06-04 | 40,765,599 | 26.98 | 1,099,855,861 |
UROV | Urovant Sciences Ltd | 2019-06-19 | 22,860,013 | 16.24 | 371,246,611 |
SIOX | Sio Gene Therapies Inc | 2019-03-18 | 13,244,048 | 0.48 | 6,330,655 |
MDVN | Medivation Inc | 2016-01-19 | 66,156 | 81.44 | 5,387,745 |
ADVM | Adverum Biotechnologies Inc | 2021-03-24 | 8,818 | 7.87 | 69,398 |
CMRX | Chimerix Inc | 2015-12-29 | 10,000 | 0.99 | 9,924 |
SCYX | SCYNEXIS Inc | 2016-09-15 | 6,000 | 1.34 | 8,040 |
Holding Weightings of Patrick Machado
Patrick Machado Form 4 Trading Tracker
According to the SEC Form 4 filings, Patrick Machado has made a total of 0 transactions in Myovant Sciences Ltd (MYOV) over the past 5 years. The most-recent trade in Myovant Sciences Ltd is the acquisition of 2,424,242 shares on June 4, 2019, which cost Patrick Machado around $20 Million.
According to the SEC Form 4 filings, Patrick Machado has made a total of 0 transactions in Urovant Sciences Ltd (UROV) over the past 5 years. The most-recent trade in Urovant Sciences Ltd is the acquisition of 18,204 shares on June 19, 2019, which cost Patrick Machado around $151,457.
According to the SEC Form 4 filings, Patrick Machado has made a total of 0 transactions in Sio Gene Therapies Inc (SIOX) over the past 5 years. The most-recent trade in Sio Gene Therapies Inc is the acquisition of 833,333 shares on March 18, 2019, which cost Patrick Machado around $10 Million.
More details on Patrick Machado's insider transactions can be found in the Insider Trading History of Patrick Machado table.Insider Trading History of Patrick Machado
- 1
Patrick Machado Trading Performance
GuruFocus tracks the stock performance after each of Patrick Machado's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Patrick Machado is 2.97%. GuruFocus also compares Patrick Machado's trading performance to market benchmark return within the same time period. The performance of stocks bought by Patrick Machado within 3 months outperforms 11 times out of 19 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Patrick Machado's insider trading performs compared to the benchmark.
Performance of Patrick Machado
Patrick Machado Ownership Network
Ownership Network List of Patrick Machado
Ownership Network Relation of Patrick Machado
Patrick Machado Owned Company Details
What does Principia Biopharma Inc do?
Who are the key executives at Principia Biopharma Inc?
Patrick Machado is the director of Principia Biopharma Inc. Other key executives at Principia Biopharma Inc include Chief Medical Officer Dolca Thomas , Chief Development Officer Stefani Wolff , and Chief Scientific Officer David M Goldstein .
Principia Biopharma Inc (PRNB) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Principia Biopharma Inc (PRNB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Principia Biopharma Inc (PRNB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Principia Biopharma Inc (PRNB)'s detailed insider trading history can be found in Insider Trading Tracker table.
Principia Biopharma Inc Insider Transactions
Patrick Machado Mailing Address
Above is the net worth, insider trading, and ownership report for Patrick Machado. You might contact Patrick Machado via mailing address: 201 Spear Street, 3rd Floor, San Francisco Ca 94107.